Krempf M, Lumbroso J, Mornex R, Brendel A J, Wemeau J L, Delisle M J, Aubert B, Carpentier P, Fleury-Goyon M C, Gibold C
University Hospital, Nantes, France.
J Nucl Biol Med (1991). 1991 Oct-Dec;35(4):284-7.
Six Medical Centers in France were involved in a prospective study evaluating the efficacy of [131I]metaiodobenzylguanidine (131I-MIBG) in the treatment of malignant pheochromocytoma. Fifteen patients aged from 28 to 75 years bearing tumor sites demonstrating a good MIBG uptake were included in this study. Catecholamines were elevated in 13/14 cases, VMA in 9/14 and metanephrines in 13/14. Two to 11 therapeutic activities of 131I-MIBG were administered, with a mean number of therapeutic doses per patient of 4 and a mean single activity of 4.7 GBq (range 2.9 to 9.25 GBq). Seven patients were alive, and seven patients died 6 to 29 months after their first MIBG administration (mean follow-up of 36 months); 1 patient was lost to follow-up. Two patients had a partial tumor response only, 4 had a hormonal response only, and 3 had both a partial tumor response and a hormonal response (complete in 2 cases). Six patients did not respond to the treatment, 4 of them died. Of the 9 responding patients, 4 relapsed, 3 of whom died subsequently. Haematological toxicity was always transient and mild, except in 1 case.
法国的六个医学中心参与了一项前瞻性研究，评估[131I]间碘苄胍（131I-MIBG）治疗恶性嗜铬细胞瘤的疗效。本研究纳入了15例年龄在28至75岁之间、肿瘤部位对MIBG摄取良好的患者。14例患者中有13例儿茶酚胺升高，9例香草扁桃酸升高，13例甲氧基肾上腺素升高。给予患者2至11次131I-MIBG治疗，每位患者的平均治疗剂量数为4次，平均单次活度为4.7 GBq（范围为2.9至9.25 GBq）。7例患者存活，7例患者在首次给予MIBG治疗后6至29个月死亡（平均随访36个月）；1例患者失访。2例患者仅出现部分肿瘤反应，4例患者仅出现激素反应，3例患者同时出现部分肿瘤反应和激素反应（2例完全缓解）。6例患者对治疗无反应，其中4例死亡。9例有反应的患者中，4例复发，其中3例随后死亡。血液学毒性除1例患者外均为短暂且轻微。
